Teva Pharmaceuticals has initiated a voluntary recall in the United States, to the patient level, of all lots of Amlodipine \/ Valsartan combination tablets and Amlodipine \/ Valsartan \/ Hydrochlorothiazide combination tablets (see table below) due to an impurity detected above specification limits in an active pharmaceutical ingredient (API) manufactured by Mylan India.
\nThe impurity found in Mylan\u2019s valsartan API is known as N-nitroso-diethylamine (NDEA), which has been classified as a probable human carcinogen. This chemical is typically found in very small amounts in certain foods, drinking water, air pollution, and certain industrial processes.<\/p>\n","protected":false},"excerpt":{"rendered":"
Teva Pharmaceuticals has initiated a voluntary recall in the United States, to the patient level, of all lots of Amlodipine \/ Valsartan combination tablets and Amlodipine \/ Valsartan \/ Hydrochlorothiazide combination tablets (see table below) due to an impurity detected above specification limits in an active pharmaceutical ingredient (API) manufactured by Mylan India. The impurity … Continue reading Teva Pharmaceuticals USA Issues Voluntary Nationwide Recall of All Amlodipine\/Valsartan Combination Tablets and Amlodipine\/Valsartan\/Hydrochlorothiazide Combination Tablets That Are Within Expiry<\/span>